Xenetic Biosciences (XBIO) Current Assets (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly Current Assets came in at $7.6 million in Q1 2026, up 38.66% YoY from $5.5 million in Q1 2025, and down 5.65% on a QoQ basis from $8.0 million in Q4 2025.
Xenetic Biosciences (XBIO) Current Assets (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 16 years of Current Assets data on file, last reported at $7.6 million in Q1 2026.
- Quarterly Current Assets rose 38.66% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (up 38.66% YoY) and the FY2025 annual result came in at $8.0 million, up 22.2% from the prior year.
- Current Assets declined to $7.6 million in Q1 2026, from $8.0 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $16.9 million in Q1 2022 to a low of $5.1 million in Q3 2025.
- A 5-year average of $9.8 million and a median of $8.4 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets surged 53.03% — and 2024, when it plunged 37.57%.
- Tracing XBIO's Current Assets over 5 years: stood at $13.7 million in 2022, then declined by 29.78% to $9.6 million in 2023, then plunged by 31.29% to $6.6 million in 2024, then advanced by 22.2% to $8.0 million in 2025, then decreased by 5.65% to $7.6 million in 2026.
- The last three Current Assets figures came in at $7.6 million (Q1 2026), $8.0 million (Q4 2025), and $5.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Xenetic Biosciences | 7.59 Mn | 1.12 Mn | - | 6.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.65 Mn |
| Mar 31, 2026 | 7.60 Mn |
| Dec 31, 2025 | 8.05 Mn |
| Sep 30, 2025 | 5.07 Mn |
| Jun 30, 2025 | 5.35 Mn |
| Mar 31, 2025 | 5.48 Mn |
| Dec 31, 2024 | 6.59 Mn |
| Sep 30, 2024 | 7.03 Mn |
| Jun 30, 2024 | 8.01 Mn |
| Mar 31, 2024 | 8.38 Mn |
| Dec 31, 2023 | 9.59 Mn |
| Sep 30, 2023 | 11.26 Mn |
| Jun 30, 2023 | 12.04 Mn |
| Mar 31, 2023 | 12.87 Mn |
| Dec 31, 2022 | 13.65 Mn |
| Sep 30, 2022 | 14.17 Mn |
| Jun 30, 2022 | 15.38 Mn |
| Mar 31, 2022 | 16.89 Mn |
| Dec 31, 2021 | 18.72 Mn |
| Sep 30, 2021 | 20.58 Mn |